Ruizhi Zhang
Key Laboratory Of Liver Transplantation, Key Laboratory Of Hepatobiliary Tumors, Jiangsu Provincial Medical Key Laboratory
Nanjing, China
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma.
Journal: Gut
Published: October 20, 2025
Ciprofol exerts anti-tumour effects in hepatocellular carcinoma through the Raf-MEK-ERK signalling pathway.
Journal: Translational gastroenterology and hepatology
Published: September 19, 2024
eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: July 02, 2024
CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.
Journal: Cancer letters
Published: December 12, 2023
Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.
Journal: Cellular and molecular gastroenterology and hepatology
Published: August 12, 2023
Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.
Journal: iScience
Published: July 19, 2023
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: March 23, 2023
Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners.
Journal: Cell metabolism
Published: September 28, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026